Q3 Asset Management Summit Therapeutics Inc. Transaction History
Q3 Asset Management
- $420 Million
- Q2 2024
Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
139Shares Held
64.4MCall Options Held
1.06MPut Options Held
1.02M-
Baker Bros. Advisors LP New York, NY23.2MShares$432 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.82MShares$164 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$147 Million0.0% of portfolio
-
State Street Corp Boston, MA4.12MShares$76.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.96MShares$55.2 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.74B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...